推荐产品
表单
powder
包装
pkg of 1 × 10 mg (880135P-10mg)
pkg of 1 × 100 mg (880135P-100mg)
pkg of 1 × 25 mg (880135P-25mg)
pkg of 1 × 50 mg (880135P-50mg)
pkg of 1 × 500 mg (880135P-500mg)
制造商/商品名称
Avanti Research™ - A Croda Brand 880135P
运输
dry ice
储存温度
−20°C
SMILES字符串
[H][C@@](COP([O-])(OCCNC(C/C=C\OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOCCOOCC(O)=O)=O)=O)(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCCCC)=O.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=
一般描述
羧酸易溶于水和乙醇等极性溶剂。DSPE-PEG（2000）羧酸由2kDa的亲水性聚乙二醇（PEG）链组成。
应用
DSPE-PEG（2000）羧酸用于：
- 将整联蛋白 α-2（ITGA2）抗体共价结合至脂质体表面
- 制备阿托西班结合的脂质体
- 制备双重互补脂质体
生化/生理作用
DSPE-PEG（2000）羧酸增加脂质体的血液循环时间。DSPE-PEG（2000）羧酸的羧基有助于和抗体共价结合。
包装
20 mL 透明玻璃螺旋盖小瓶 (880135P-500 mg)
5 mL 棕色玻璃螺旋盖小瓶 (880135P-10 mg)
5 mL 棕色玻璃螺旋盖小瓶 (880135P-100 mg)
5 mL 棕色玻璃螺旋盖小瓶 (880135P-25 mg)
5 mL 棕色玻璃螺旋盖小瓶 (880135P-50 mg)
法律信息
Avanti Research is a trademark of Avanti Polar Lipids, LLC
通常也和此产品一起购买
产品编号
说明
价格
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
No data available
闪点(°C)
No data available
ITGA2 as a potential nanotherapeutic target for glioblastoma
Guo P, et al.
Scientific reports, 9(1), 6195-6195 (2019)
Carboxylic Acid: Key Role in Life Sciences (2019)
Mohammad Mashreghi et al.
Nanoscale research letters, 15(1), 101-101 (2020-05-10)
In this study, we have surface-functionalized PEGylated-nanoliposomal doxorubicin (DOX) with anti-EpCAM (epithelial cell adhesion molecule) aptamer via post-insertion of anti-EpCAM aptamer-conjugated DSPE-mPEG2000 into Caelyx® (ED-lip). The size, charge, release profile, and cytotoxicity and cellular uptake of formulation were determined. The
Junxue An et al.
Journal of colloid and interface science, 577, 92-100 (2020-05-31)
Phospholipids constitute biocompatible and safe excipients for pulmonary drug delivery. They can retard the drug release and, when PEGylated, also prolong the residence time in the lung. The aim of this work was to assess the structure and coherence of
Feifei Yang et al.
Small (Weinheim an der Bergstrasse, Germany), 16(7), e1906360-e1906360 (2020-01-24)
Hepatotoxicity is a key concern in the clinical translation of nanotherapeutics because preclinical studies have consistently shown that nanotherapeutics accumulates extensively in the liver. However, clinical-stage nanotherapeutics have not shown increased hepatotoxicity. Factors that can contribute to the hepatotoxicity of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门